Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK patent portfolio — 48 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
5
Drugs
69
Patents
48
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Regeneron UK patents

48 pharmaceutical patents indexed for Regeneron UK. 0 expire within 24 months.

Regeneron UK has 48 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

48 patents

Patent portfolio

  1. US 12280093

    Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12268730

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12202883

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12168036

    Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12116622

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12077570

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12054533

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11986511

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11975045

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11904017

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11769597

    Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11753459

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11732025

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11732024

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11707506

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11649273

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11559564

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11548932

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11542317

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11535663

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11505593

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11485770

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11472861

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11459373

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11459374

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11306135

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11299532

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11253572

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11186625

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11174283

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11103552

    High concentration VEGF receptor fusion protein containing formulations

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11104715

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11084865

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11071780

    Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11066458

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11053280

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10973879

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10888601

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10857231

    Formulations of VEG antagonist fusion proteins and method of manufacturing them

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10857205

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10828345

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10772956

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10406226

    Method of manufacturing VEGF antagonist fusion proteins

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10130681

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9669069

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9254338

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7070959

    Modified chimeric polypeptides with improved pharmacokinetic properties

    Expires Mon Jun 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

48 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.